CHAPEL EN LE FRITH, England, January 9 /PRNewswire/ -- Peakdale
Molecular Ltd a leading provider in specialist chemistry services to the
pharmaceutical industry has announced today that they have successfully
completed a GBP1m round of equity funding which will enable Peakdale to
continue the expansion of its facilities in the UK to support its continued
rapid growth.
The investors in this round were led by Solon Ventures LP, advised by
Solon Ventures Ltd, and were supported by a number of existing investors.
Commenting on the deal, Peakdale's Commercial Director Ray Fisher said:
"I am very grateful for being introduced to the team at Solon Ventures at
such an important time in Peakdale's history. With our plans for aggressive
growth, Solon's sector knowledge and desire to actively support such
activities, together we appear to have the ingredients of a perfect
synergy."
Adding to this, Solon Ventures Ltd Managing Director Angus Whiteley
said: "We are delighted to be involved with Ray and his team at Peakdale in
this exciting stage of its development. With its excellent reputation and
high quality services, we believe Peakdale is very well placed to continue
to support the pharmaceutical and biotech industries in the future. We look
forward to playing an active role, based on our experience of the sector,
in helping the company achieve its growth and international aspirations."
About Peakdale Molecular
Peakdale Molecular was founded in 1992. Today the Company's customers
include the majority of the major global pharmaceutical companies and an
increasing number of biotechnology companies. Its teams of chemists combine
experience in pharmaceutical R&D and process development, medicinal
chemistry, parallel synthesis and fine chemicals to deliver unique
chemistry solutions to a range of drug discovery challenges.
The application of less commonly used chemistry, including high
temperature/pressure reactions, proprietary heterocyclic chemistry and
nucleoside synthesis, enables Peakdale's chemists to generate unique
compounds for drug discovery. Peakdale operates in several distinct markets
providing novel screening compounds, targeted screening libraries,
catalogue intermediates, custom synthesis and contract research. Further
information about the Company can be obtained at http://www.peakdale.com
About Solon Ventures LP
Solon Ventures LP is a Jersey-based limited partnership that invests in
private UK healthcare and technology companies. The fund is advised by Solon
Ventures Ltd, a UK company that advises GBP35m of venture capital investment
for a range of clients.
Peakdale Molecular
Ray Fisher
Commercial Director
Peakdale Molecular Ltd
Peakdale Science Park
Sheffield Road
Chapel-en-le-Frith
High Peak
SK23 0PG
UK
Tel +44(0)1298-816700
Fax +44(0)1298-816701
http://www.peakdale.com
Angus Whiteley
Managing Director
Solon Ventures Ltd
24 Old Bond Street
London
W1S 4AW
UK
Tel +44(0)20-7535-4912
Fax +44(0)20-7493-9172
http://www.solonventures.com
SOURCE Peakdale Molecular
 back to top
CONTACT:
Peakdale Molecular, Ray Fisher, Commercial
Director, Peakdale Molecular Ltd, Peakdale Science Park,
Sheffield Road, Chapel-en-le-Frith, High Peak, SK23 0PG, UK, Tel
+44(0)1298-816700, Fax +44(0)1298-816701; Angus Whiteley,
Managing Director, Solon Ventures Ltd, 24 Old Bond Street,
London, W1S 4AW, UK, Tel +44(0)20-7535-4912, Fax
+44(0)20-7493-9172
|
